期刊文献+

XPD Lys751Gln核苷酸多态性与皮肤黑色素瘤易感性关系的Meta分析 被引量:1

Correlation between the XPD Lys751Gln nucleotide polymorphisms and cutaneous melanoma:a Meta-analysis
下载PDF
导出
摘要 目的:采用Meta分析方法评价XPD Lys751G1n核苷酸多态性与皮肤黑色素瘤(cutaneous melanoma,CM)的相关性。方法:全面检索相关文献,采用Stata12.0软件进行统计分析。结果:共纳入9个病例一对照研究。在Lvs751GIn多态性位点等位基因模式中,与野生基因型A相比,C合并的OR值(95%CI)为1.05(1.01~1.09);显性模式中与AA相比,CC+CA合并的0R值(95%CI)为1.13(1.03~1.24);共显性模式中与AA相比,CC合并的OR值(95%CI)为1.04(1.00-1.08);其余为阴性结果。结论:C等位基因可能是CM的易感基因。 Objective To evaluate the correlation between Lys751 Gin nucleotide polymorphisms and cutaneous melanoma (CM) by meta analysis. Methods Relevant literatures were searched and then the meta-analysis was conducted by Stata 12.0 software. Results A total of 9 case-control studies were involved. In allele model of Lys751Gln polymorphism, the OR value of genotype C was 1.05 (95% CI was 1.01- 1.09) as compared to wild genotype A. In dominant model, the OR value of CC+CA was 1.13 (95% CI was 1.03 - 1.24) as compared to AA. In co-dominant model, the OR value of CC was 1.04 (95%CI was 1.00-1.08) as compared to AA. The emaining results were negative. Conclusion C allele may be the susceptibility marker gene of CM.
出处 《实用医学杂志》 CAS 北大核心 2013年第19期3237-3240,共4页 The Journal of Practical Medicine
基金 广西壮族自治区科学技术厅基金资助项目(编号:桂科攻1140003B-86)
关键词 黑色素瘤 Lyrs751Gln 基因多态性 META分析 Melanoma Lys751Gln Polymorphism Meta-analysis
  • 相关文献

参考文献13

  • 1Gershenwald J E, Giacco G G, Lee J E. Cutaneous Melanoma [M]// 60 Years of survival outcomes at The University of Texas MD Anderson Cancer Center. Springer, 2013:153-165.
  • 2王园园,王义善,王鑫,杨柯,杨桂青.PI3K/Akt信号通路与恶性黑色素瘤浸润转移的研究进展[J].实用医学杂志,2012,28(2):322-323. 被引量:7
  • 3Alberg A J, Jorgensen T J, Ruczinski I, et al. DNA repair gene variants in relation to overall cancer risk: a population- based study [J]. Carcinogenesis, 2013, 34(1): 86-92.
  • 4Wlodarczyk M, Nowicka G. XPD gene rs13181 polymorphism and DNA damage in human lymphocytes [J]. Biochem Genet, 2012, 50(11-12): 860-870.
  • 5Winsey S L, Haldar N A, Marsh H P, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer [J]. Cancer Res, 2000, 60(20) : 5612-5616.
  • 6Baccarelli A, Calista D, Minghetti P, et al. XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk [J]. Br J Cancer, 2004, 90(2) : 497-502.
  • 7Han J, Colditz G A, Liu J S, et al. Genetic variation in XPD, sun exposure, and risk of skin cancer [J]. Cancer Epidemiol Biomarkers Prey, 2005, 14(6): 1539-1544.
  • 8Debniak T, Scott R J, Huzarski T, et al. XPD common variants and their association with melanoma and breast cancer risk [Jl. Breast Cancer Res Treat, 2006, 98(2): 209-215.
  • 9Li C, Hu Z, Liu Z, et al. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis [J]. Cancer Epidemiol Biomarkers Prey, 2006, 15(12): 2526-2532.
  • 10Millikan R C, Hummer A, Begg C, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study [J]. Carcinogenesis, 2006, 27(3): 610-618.

二级参考文献16

  • 1胡蕾,姜汉国.PI3K/AKT信号转导通路与肿瘤转移及其机制的研究进展[J].医学综述,2006,12(22):1375-1377. 被引量:18
  • 2Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma European consensus based interdisciplinary guideline[J]. Eur J Cancer, 2010,46(2) :270-283.
  • 3Lin Y, Han C D, Mei S, et al. Akt/ protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt [J]. Cancer Res, 2004,64(13) :4394.
  • 4Alex T, Merav Y L. Akt Signaling and cancer surviving but not moving on[J]. Cancer Res, 2006,66(9) :3963-3966.
  • 5Hara S, Oya M, Mizuno R, et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor [J]. Ann Oncol, 2005,16(6) :928.
  • 6Brick A, Ahrenkiel V, Zenthen J, et al. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies [J]. J Invest Dermatol, 2000,114(2) :227-280.
  • 7Risinger J I, Hayes K, Maxwell G L,et al. PTEN mutation in endometrial cancer is associated with favorable clinical andpathologic characteristics [J]. Clin Cancer Res, 1998,4(12) : 3005.
  • 8Cantl Eylc, Neel B G. New insights into tumor suppression: HEN suppresses tumor formation by restraining thephosphoinositide 3-kinase/ AKT pathway [J]. Proc Natl Acad Sci USA, 1999, 96(8) :4240-4245.
  • 9Huang S, Houghton P J. Targeting mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol, 2003,3(4) :371- 377.
  • 10Qian Y, Corum L, Meng Q, et al. PI3K induced actin filament remodeling through Akt and p70S6K1 : implication of essential role in cell migration [J]. Am J Physiol Cell Physiol, 2004,286 (9) : 153-163.

共引文献6

同被引文献23

  • 1Searles Nielsen S,Bammler TK,Gallagher LG,et al. Genotype and age at Parkinson disease diagnosis [ J ]. Int J Mol Epidemiol Genet,2013 ,4( 1) : 61-69.
  • 2Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinsons disease using single nucleotide polymorphisms [ J ]. Ann Neurol, 2002,51(1) : 133-136.
  • 3Wtillner U,Kolsch H,Linnebank M. Methylenetetrahydro- folate reductase in Parkinson^s disease [J]. Ann Neurol, 2005,58(6) : 972-973.
  • 4Caccamo D,Gorgone G,Curro M,et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa- treated Parkinsonian patients [ J ]. Neuromolecular Med, 2007,9(3) : 249-254.
  • 5Dorszewska J, Florczak J, Rozycka A, et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases [J]. Acta Neurobiol Exp (Wars), 2007,67(2) : 113-129.
  • 6Camicioli RM,Bouchard TP,Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients [ J ]. Mov Disord,2009,24(2) : 176-182.
  • 7Yuan RY,Sheu JJ,Yu JM,et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease pa- tients[J]. J Neurol Sci ,2009,287( 1-2) : 64-68.
  • 8Rodriguez-Oroz MC,Lage PM, Sanchez-Mut J,et al. Ho-mocysteine and cognitive impairment in Parkinson^s disease :a biochemical,neuroimaging,and genetic study[J]. Mov Disord,2009,24(10) : 1437-1444.
  • 9Biaiecka M,Kurzawski M,Roszmann A,et al. Association of COMT,MTHFR,and SLC19A1 ( RFC-1 ) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson^s disease [ J ]. Pharmacogenet Ge- nomics,2012,22(10) : 716-724.
  • 10Castro R,Rivera I,Ravasco P,et al. 5,10-methylenetetra- hydrofolate reductase (MTHFR) 677C-T and 1298A- C mutations are associated with DNA hypomethylation [J]. J Med Genet,2004,41(6) : 454-458.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部